Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

Stewart, David J; Ramsay, Tim; Navani, Vishal; Liu, Geoffrey; Jiang, Di Maria; Batist, Gerald

Stewart, David J; Ramsay, Tim; Navani, Vishal; Liu, Geoffrey; Jiang, Di Maria; Batist, Gerald.

Afiliação

Stewart DJ; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro
Ramsay T; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro
Navani V; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro
Liu G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro
Jiang DM; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro
Batist G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toro

J Clin Oncol ; 42(8): 973-974, 2024 Mar 10.

Article em En | MEDLINE | ID: mdl-38290085

Assuntos

Antineoplásicos; Neoplasias; Humanos; Intervalo Livre de Progressão; Neoplasias/tratamento farmacológico; Antineoplásicos/uso terapêutico; Intervalo Livre de Doença

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_medicamentos_vacinas_tecnologias Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: J Clin Oncol / J. clin. oncol / Journal of clinical oncology Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google